Baltimore, MD – According to filings with the U.S. Securities and Exchange Commission, Elixirgen Therapeutics is raising $5,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Akihiro Ko played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Elixirgen Therapeutics
Elixirgen Therapeutics is a biotechnology company focused on curing humanitys ailments through stem cell biology. Founded in 2017 by Minoru S.H. Ko, M.D., Ph.D., a renowned specialist in stem cell biology, the company concentrates on regenerative and rejuvenative medicine, and deals with research in both basic science and in the application of the technologies it discovers and refines. Elixirgen Therapeutics is located in the Science + Technology Park at Johns Hopkins in Baltimore, an ideal research environment that allows Elixirgen Therapeutics scientists to conduct research at state-of-the-art facilities. Elixirgen Therapeutics inherits all the therapy-related assets, including intellectual property, from its parent company, Elixirgen, LLC, which has been in active operation since the beginning of 2012.

To learn more about Elixirgen Therapeutics, visit http://elixirgentherapeutics.com/

Contact:
Akihiro Ko, Chief Executive Officer
443-451-5300
https://www.linkedin.com/in/akihiro-ko-2a67404b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved